BRUSSELS (EFE) .— The European Commission yesterday authorized the marketing of the vaccine developed by the BioNTech laboratory and the pharmaceutical company Pfizer adapted to the sub-variants BA.4 and BA.5 of Ómicron, which a few hours earlier had been supported by the European Agency for Medicines (EMA).
Community executive health commissioner, Stella Kyriakides, confirmed the authorization on Twitter after learning that the serum has had positive analysis from the EMA and stressed that the authorization “will ensure that member states will be in able to deploy it quickly to protect citizens ”.
“We know Covid is still a threat. This is why we have just authorized the booster dose of BioNTech and Pfizer against the current variants ”, emphasized, for her part, the President of the European Commission, Ursula von der Leyen.
–